Store

Clinical Trials

Why Clinical Trials?

Angiosarcoma Clinical Trials

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. “Investigational” means that the drug […]
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved Eribulin for your specific disease but it has been approved for other uses. In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE. Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules
More Information
Status
Recruiting
Collaborators
Eisai Inc.

A Randomized Phase 3 Trial of TRC105 and Pazopanib versus Pazopanib Alone in Patients with Advanced Angiosarcoma

Phase III
The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.
This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.
More Information
Status
Recruiting

Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of […]
The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might normally help the cancer cells grow or form new blood vessels that could feed a growing tumor. By blocking these proteins, regorafenib may help stop the growth of certain cancers.
More Information
Status
Recruiting
Collaborators
Bayer, National Cancer Institute (NCI)

Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
The purpose of this research study is to look at whether giving a drug called dexrazoxane plus olaratumab with standard of care doxorubicin affects the progression of the disease. Dexrazoxane is often given at the same time as doxorubicin to help reduce the incidence and severity of disease of the heart muscle (which can be […]
The purpose of this research study is to look at whether giving a drug called dexrazoxane plus olaratumab with standard of care doxorubicin affects the progression of the disease. Dexrazoxane is often given at the same time as doxorubicin to help reduce the incidence and severity of disease of the heart muscle (which can be caused by doxorubicin).
More Information
Status
Recruiting

Evaluation of Votrient in Angiosarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.   *Please note that this trial currently only has sites in Germany.
Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.   *Please note that this trial currently only has sites in Germany.
More Information
Status
Recruiting
Collaborators
Universitätsmedizin Mannheim; HELIOS Klinikum Berlin-Buch; University Hospital Dresden; Universitätsklinikum Hamburg-Eppendorf; University Hospital, Essen; Hannover Medical School; Klinikum der Universitaet Muenchen, Grosshadern; Medical University of Vienna; Medical University of Graz; Medical University Innsbruck; GlaxoSmithKline

Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib […]
This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether gemcitabine hydrochloride is more effective with or without pazopanib hydrochloride in treating patients with soft tissue sarcoma.
More Information
Status
Recruiting
Collaborators
National Cancer Institute (NCI)

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
More Information
Status
Recruiting
Collaborators
National Cancer Institute (NCI)

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Phase I
Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
This phase Ib trial studies the side effects and best dose of the CDK4/6 inhibitor ribociclib when given together with doxorubicin in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed by surgery. Ribociclib may stop the growth of sarcoma tumor cells by blocking some of the […]
This phase Ib trial studies the side effects and best dose of the CDK4/6 inhibitor ribociclib when given together with doxorubicin in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed by surgery. Ribociclib may stop the growth of sarcoma tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib for a week prior to standard treatment with doxorubicin may work better in treating patients with soft tissue sarcoma.
More Information
Status
Recruiting
Collaborators
National Cancer Institute (NCI)

Sarcoma Clinical Trials

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
The goal of this clinical research study is to learn if the combination of durvalumab and tremelimumab can help to control sarcoma. The safety of this drug combination will also be studied. This is an investigational study. Durvalumab and tremelimumab are not FDA approved or commercially available. They are currently being used for research purposes […]
The goal of this clinical research study is to learn if the combination of durvalumab and tremelimumab can help to control sarcoma. The safety of this drug combination will also be studied. This is an investigational study. Durvalumab and tremelimumab are not FDA approved or commercially available. They are currently being used for research purposes only. The study doctor can explain how the study drugs are designed to work.
More Information
Status
Recruiting
Collaborators
MedImmune LLC

Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma

Phase III
The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
This randomized phase III trial is studying radiation therapy followed by surgery to see how well it works compared with surgery alone in treating patients with previously untreated nonmetastatic retroperitoneal soft tissue sarcoma.
This randomized phase III trial is studying radiation therapy followed by surgery to see how well it works compared with surgery alone in treating patients with previously untreated nonmetastatic retroperitoneal soft tissue sarcoma.
More Information
Status
Recruiting

Soft Tissue Sarcoma Clinical Trials

ADI- PEG 20 in Combination with Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma

Phase II
The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
The purpose of this study is to evaluate the effectiveness of an investigational drug (ADI-PEG 20) in combination with two established types of chemotherapy in treating soft tissue sarcoma, including angiosarcoma. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn […]
The purpose of this study is to evaluate the effectiveness of an investigational drug (ADI-PEG 20) in combination with two established types of chemotherapy in treating soft tissue sarcoma, including angiosarcoma. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
More Information
Status
Recruiting
Collaborators
Polaris Pharmaceuticals, Inc.

Solid Metastatic Tumor Clinical Trials

There are currently no trials on-going.

All content of this Site, such as text, graphics, images, comments, information, and other material contained on this site are for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on Angiosarcoma’s website or affiliated social media accounts.

If you think you may have a medical emergency, call your doctor or 911 immediately. Angiosarcoma Awareness does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the site. Reliance on any information provided by Angiosarcoma Awareness, Inc., Angiosarcoma Awareness members, or others appearing on the site at the invitation of Angiosarcoma Awareness, or other visitors to the Site is solely at your own risk.